Holen Sie sich die Stockscreener-App
8.60
11.40%
0.88
Handel nachbörslich:
8.50
-0.10
-1.16%
Schlusskurs vom Vortag:
$7.72
Offen:
$8.17
24-Stunden-Volumen:
2.64M
Relative Volume:
1.13
Marktkapitalisierung:
$465.98M
Einnahmen:
$1.02B
Nettoeinkommen (Verlust:
$-757.20M
KGV:
-0.7119
EPS:
-12.08
Netto-Cashflow:
$-257.90M
1W Leistung:
-28.15%
1M Leistung:
-8.02%
6M Leistung:
+54.95%
1J Leistung:
+319.51%
1-Tages-Spanne:
$7.81
$8.72
1-Wochen-Bereich:
$7.71
$11.65
52-Wochen-Spanne:
$1.42
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Vergleichen Sie EBS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| EBS | 8.60 | 465.98M | 1.02B | -757.20M | -257.90M | -12.08 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
Insider Sale: Director Donald Degolyer Sells 25,000 Shares of Em - GuruFocus.com
Emergent BioSolutions director Donald DeGolyer sells $272,750 in stock - Investing.com
Emergent BioSolutions director Donald DeGolyer sells $272,750 in stock By Investing.com - Investing.com UK
Oak Hill Advisors LP's Strategic Acquisition of Emergent BioSolu - GuruFocus.com
Insider Sale: Director Marvin White Sells 14,287 Shares of Emergent BioSolutions Inc (EBS) - GuruFocus.com
Smallpox Treatment Market Is Anticipated To Grow In A Promising - openPR
Emergent BioSolutions Inc (EBS) Shares Down 8.02% on Nov 12 - GuruFocus.com
IDWeek 2024: strategic approaches and challenges in mpox vaccination - Pharmaceutical Technology
Emergent BioSolutions Inc. (NYSE:EBS) Q3 2024 Earnings Call Transcript - MSN
Emergent BioSolutions Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Emergent BioSolutions (NYSE:EBS) Shares Up 7.9% After Analyst Upgrade - MarketBeat
Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic (NYSE:EBS) - Seeking Alpha
Emergent Biosolutions Stock Soars After Q3 Earnings: Retail Sentiment Strong - MSN
Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise - Benzinga
Emergent BioSolutions Inc (EBS) Quarterly 10-Q Report - Quartzy
Emergent BioSolutions entering ‘turnaround’ phase, new CEO says - The Business Journals
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 - Yahoo Finance
Crude Oil Rises 1%; US Jobless Claims Increase To 221,000 - Benzinga
Emergent BioSolutions (NYSE:EBS) Shares Gap Up on Analyst Upgrade - MarketBeat
Emergent Biosolutions Shares Surge 28% After Swinging to 3Q Profit - MarketWatch
Emergent BioSolutions stock target increased, keeps buy on strong Q3 By Investing.com - Investing.com UK
The Post-Trump Victory TradeEmergent BioSolutions (NYSE:EBS), Bit Digital (NASDAQ:BTBT) - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Emergent Biosolutions: Q3 Earnings Snapshot - Houston Chronicle
Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript - AOL
Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates - Yahoo Finance
Emergent Biosolutions stock jumps 14% post-market on guidance raise (NYSE:EBS) - Seeking Alpha
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa - The Manila Times
The Escalator: Emergent BioSolutions, CureVac, Kyowa Kirin and more - MM+M Online
Emergent BioSolutions Reports Third Quarter 2024 Financial Results - The Manila Times
Emergent BioSolutions Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Emergent Bio slips after financing deal - MSN
Emergent BioSolutions appoints new chief medical officer By Investing.com - Investing.com Canada
Biotech Co. Emergent Gives Interim GC Permanent Role - Law360
Emergent BioSolutions appoints new chief medical officer - Investing.com
Emergent BioSolutions (EBS) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Emergent Bio's smallpox vaccine gets US approval for mpox - AOL
Assenagon Asset Management S.A. Increases Stock Position in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way? - Simply Wall St
Zacks.com featured highlights include American Airlines, Air Canada, EmergentBioSolutions, Berry and Cracker Barrel Old Country Store - Yahoo Finance
5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades - Yahoo Finance
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - GlobeNewswire Inc.
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 - The Manila Times
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference - The Bakersfield Californian
Emergent BioSolutions (NYSE:EBS) Shares Up 3.2%Here's What Happened - MarketBeat
Biopharma Layoffs Roundup - Contract Pharma
Zacks.com featured highlights include Grupo Supervielle, Emergent BioSolutions and Innodata - Yahoo Finance
3 Stocks Poised for Better Returns With New Analyst Coverage - Yahoo Finance
Emergent BioSolutions Inc. (NYSE:EBS) Short Interest Up 84.1% in September - MarketBeat
Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):